Rare diseases
Investigational molecules
Locations
706 conditions with trials, the busiest first
3 926 trials across Europe, recruiting first
Study on the Safety and Effectiveness of HDP-101 for Patients with Relapsed or Refractory Multiple Myeloma
GermanyStudy of Linvoseltamab in Adults with Relapsed or Refractory Multiple Myeloma
BelgiumStudy on Letrozole Maintenance Therapy for Patients with Epithelial Ovarian Cancer
AustriaStudy on the Effectiveness of Yttrium-90 Microspheres and Capecitabine for Patients with Operable Intrahepatic Cholangiocarcinoma
FranceStudy on F-18 PSMA-11 PET Imaging for Liver Cancer in Patients to Evaluate Survival
BelgiumLong-term safety study of Temferon (modified stem cells with interferon-α2) in patients previously treated for glioblastoma multiforme
ItalyStudy of Gilteritinib, Venetoclax, and Azacitidine for Patients with Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutations Not Eligible for Intensive Treatment
GermanyStudy on Crizotinib for Treating Severe Neurofibromatosis Type 2 in Children Not Eligible for Surgery or Radiotherapy
PolandStudy of tislelizumab immunotherapy in patients with liver cancer (hepatocellular carcinoma) who have moderately impaired liver function (Child-Pugh B)
FranceStudy on the Safety of Encorafenib, Binimetinib, and Ribociclib for Patients with Solid Tumors
CzechiaStudy on Treating Solid Tumors with Genetically Modified T-Cells (IMA203, IMA203CD8) and Nivolumab for Patients with Recurrent or Refractory Conditions
GermanyStudy of azacitidine combined with low-dose venetoclax treatment for patients with acute myeloid leukemia
DenmarkThe therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
